國家衛生研究院 NHRI:Item 3990099045/12264
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 858682      在线人数 : 699
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/12264


    题名: Interpretation the results of adjuvant chemotherapy in curatively resected pancreatic cancer
    作者: Chen, LT
    贡献者: National Institute of Cancer Research
    摘要: ESPAC-1 has established the role of adjuvant systemic chemotherapy in patients with pancreatic cancer after curative-intent resection. Recent observation-controlled studies further demonstrated that 6 months of gemcitabine monotherapy could double the recurrence-free survival, from 5.0-6.7 to 11.4-13.4 months, and reduced risk of death by 23-24% as compared to observation alone. Of interesting to note, the recurrence-free survival of patients receiving gemcitabine monotherapy decreased from 13.4-14.3 months in the CONKO-001 and ESPAC-3 and -4 studies to 11.3-12.8 months in the more recent launched CONKO-005 and PRODIGY 24/CCTG PA.6 studies. However, the median overall survival of those patients improved from 22.8 months in the 1998 launched CONKO-001 study to 26.5 months in the 2008 launched CONKO-005 study and 34.8 months in the 2012 launched PRODIGY 24/CCTG PA.6 study. The difference in median overall survival and median recurrence-free survival increased from 9.4 to 22.0 months during the 15-year period of time. Actually, several factors have been considered affect the median RFS and/or OS of patients with pancreatic cancer after the R0/R1 resection, such as the emergence of more effective primary chemotherapy for patients with recurrent or metastatic diseases, FOLFIRINOX and nab-paclitaxel plus gemcitabine, after 2010 and 2013, the applications of regular surveillance for early recurrence detection, the inclusion of patients with high CA 19.9 level and/or the proportion of patients with R0/R1 resection as well as the use of different definition of R0 resection, and dose intensity of adjuvant chemotherapy, etc. All of which will be discussed in the meeting.
    日期: 2019-10
    關聯: Annals of Oncology. 2019 Oct;30(Suppl. 6):vi 78.
    Link to: http://dx.doi.org/10.1093/annonc/mdz373
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0923-7534&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000491239300404
    显示于类别:[陳立宗] 會議論文/會議摘要

    文件中的档案:

    档案 描述 大小格式浏览次数
    ISI000491239300404.pdf71KbAdobe PDF280检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈